The only one thing more valuable to development-stage drugmakers than cash is cash that doesn't dilute shareholders. Novavax
The contract offers $97 million over three years with the potential for an additional $82 million if the contract is extended for two more years. That's a heck of a lot of money for a company that had just $37 million in cash and short-term investments at the end of September.
Traditional flu vaccines made by Novartis
Novavax's contract will finance a manufacturing facility that can reduce the development time down to just three months. Scaling up production using Novavax's system is also a lot easier than it is in chicken eggs, where you need about one egg for every dose of vaccine produced. Novavax hopes to be able to produce 50 million doses within six months of a pandemic flu outbreak.
All of this, of course, depends on the vaccine actually working. Novavax plans to run a phase 2 trial this year and then move its seasonal flu vaccine into phase 3 development in 2012. The pandemic flu vaccine is a little farther behind, but one can assume it would take the lead should the swine flu, bird flu, or some other animal flu rear its ugly head.
Even after an increase over the last two years, Novavax should still have plenty of room to run, but it won't get there until the vaccine makes it to market, which is years away. There's potential for earlier sales if a pandemic flu hits, but who want to use that as their investment thesis?
Interested in keeping track of Novavax as it develops its vaccine? Click here to add it to My Watchlist, which will help you keep track of all our Foolish analysis on Novavax.
GlaxoSmithKline and Novartis AG are Motley Fool Global Gains selections. The Fool owns shares of GlaxoSmithKline. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.